Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Claudins are a large family of tetraspan transmembrane proteins that constitute the principal structural components of tight junctions in epithelial and endothelial cells[1][2][6]. They form networks at cell-cell contacts that regulate paracellular transport—the movement of ions, water, and small molecules between adjacent cells—thereby establishing selective barriers critical for tissue homeostasis[1][2]. Each member has four transmembrane domains with two extracellular loops; these loops mediate both homophilic interactions with other claudins on neighboring cells (“trans” interactions) and lateral associations within the same membrane (“cis” interactions), determining both charge selectivity and overall permeability properties[6]. There are over 20 known mammalian claudin isoforms with distinct tissue distributions; their differential expression patterns underlie specialized functions across organs such as kidney tubules, lung alveoli, liver bile ducts, brain endothelium (blood-brain barrier), among others[7]. Alterations in expression levels or mutations affecting specific claudins have been implicated in various diseases including carcinomas—where they may serve both functional roles in metastasis/invasion pathways as well as diagnostic/prognostic biomarkers—and inflammatory disorders where compromised barrier function leads to pathological leakage across epithelia/endothelia[8]. While not classical drug targets like receptors or enzymes due to their structural role at intercellular contacts rather than signaling per se,[9] certain disease-associated isoforms have become targets for antibody-based therapeutics currently under clinical development. In summary: The “Epithelial tight junction protein Claudin” refers collectively to members of the *claudin* family—key determinants of intercellular sealing within tissues—which play essential roles in health by maintaining compartmentalization but also contribute pathologically when dysregulated.
Experimental drugs/antibodies may act by binding to extracellular loops of specific claudins to disrupt tumor cell adhesion or modulate tight junction integrity; this can lead to increased immune recognition or altered tissue permeability.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Claudin tight junction protein (Claudin).